These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19279022)

  • 1. Evaluation of a surveillance programme for women with a family history of breast cancer.
    Reis MM; Tavakoli M; Dewar J; Goudie D; Cook A; McLeish L; Young D; Kenyon J; Steel M
    J Med Genet; 2009 May; 46(5):319-23. PubMed ID: 19279022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding the criteria for BRCA mutation testing in breast cancer survivors.
    Kwon JS; Gutierrez-Barrera AM; Young D; Sun CC; Daniels MS; Lu KH; Arun B
    J Clin Oncol; 2010 Sep; 28(27):4214-20. PubMed ID: 20733129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
    Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
    J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women.
    Taneja C; Edelsberg J; Weycker D; Guo A; Oster G; Weinreb J
    J Am Coll Radiol; 2009 Mar; 6(3):171-9. PubMed ID: 19248993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI screening in a clinic population with a family history of breast cancer.
    Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA
    Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening younger women with a family history of breast cancer--does early detection improve outcome?
    Maurice A; Evans DG; Shenton A; Ashcroft L; Baildam A; Barr L; Byrne G; Bundred N; Boggis C; Wilson M; Duffy SW; Howell A
    Eur J Cancer; 2006 Jul; 42(10):1385-90. PubMed ID: 16750910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.
    Kaas R; Muller SH; Hart AA; Rutgers EJ
    Eur J Surg Oncol; 2008 May; 34(5):501-7. PubMed ID: 17555911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The study of cost effectiveness of breast cancer detection in Catalonia].
    Plans P; Casademont L; Tarín A; Navas E
    Rev Esp Salud Publica; 1996; 70(1):15-23. PubMed ID: 8991697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial results of a study into the effectiveness of breast cancer screening in a population identified to be at high risk.
    Myles J; Duffy S; Nixon R; Boggis C; Howell A; Shenton A; Evans G
    Rev Epidemiol Sante Publique; 2001 Oct; 49(5):471-5. PubMed ID: 11845096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia.
    Groot MT; Baltussen R; Uyl-de Groot CA; Anderson BO; Hortobágyi GN
    Breast J; 2006; 12 Suppl 1():S81-90. PubMed ID: 16430401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach.
    Granader EJ; Dwamena B; Carlos RC
    Acad Radiol; 2008 Dec; 15(12):1590-5. PubMed ID: 19000876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An interim determination of health gain from oral cancer and precancer screening: 2. Developing a model of population screening.
    Downer MC; Jullien JA; Speight PM
    Community Dent Health; 1997 Dec; 14(4):227-32. PubMed ID: 9458580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
    Lyman GH; Lalla A; Barron RL; Dubois RW
    Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis.
    Marino P; Roché H; Moatti JP;
    Am J Clin Oncol; 2008 Apr; 31(2):117-24. PubMed ID: 18391594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A workplace breast cancer screening program. Costs and components.
    Schrammel P; Griffiths RI; Griffiths CB
    AAOHN J; 1998 Nov; 46(11):523-9. PubMed ID: 9934000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the economic burden of breast cancer in a US managed care population.
    Barron JJ; Quimbo R; Nikam PT; Amonkar MM
    Breast Cancer Res Treat; 2008 May; 109(2):367-77. PubMed ID: 17674201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost analysis of the National Breast and Cervical Cancer Early Detection Program: selected states, 2003 to 2004.
    Ekwueme DU; Gardner JG; Subramanian S; Tangka FK; Bapat B; Richardson LC
    Cancer; 2008 Feb; 112(3):626-35. PubMed ID: 18157831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a community-based intervention to enhance breast cancer screening practices in Brazil.
    Thuler LC; Freitas HG
    J Eval Clin Pract; 2008 Dec; 14(6):1012-7. PubMed ID: 18759754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of care in early-stage breast cancer survivors in the first year after cessation of active treatment.
    Mandelblatt JS; Lawrence WF; Cullen J; Stanton AL; Krupnick JL; Kwan L; Ganz PA
    J Clin Oncol; 2006 Jan; 24(1):77-84. PubMed ID: 16382116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.